Carving a Niche in Saliva-Based Diagnostics
Given that most diagnostics deals are valued at one to two times sales, $150 million to $200 million may seem like a lot of money to pay for a company with less than $20 million in sales, but that's the value Epitope is placing on STC Technologies Inc. The stock deal aligns two companies who have been working together for some time, positioning them as a leader in the small but growing oral fluid and point-of-care diagnostics market.
You may also be interested in...
OraSure Technologies is first (with the exception of an outdated, complicated test sold by Abbott) to get coveted FDA approval for a rapid HIV diagnostic test, and it also won a hard-to-get CLIA waiver for the test after a one-day review by the Department of Health and Human Services; the waiver enables the test to be used in a much wider variety of non-laboratory settings. The company's opportunity looks huge, but the test's success is far from a sure bet.
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.